If recently approved treatments are any indication, gene therapies may release with an average price of ~$3 million per course of treatment. The staggering cost of these therapies was supported by ICER due to the long-term reduction in cost of care that they provide. Although these prices tend to come with refunds if the treatment isn’t effective, not all payers are on-board.
According to Zachary Brennan, “Still, when Zynteglo first won European approval in 2019, the nearly $2 million price tag seemed like a surmountable hurdle, but the therapy has since been withdrawn as the company struggled with reimbursement, and with its finances, eventually laying off almost a third of its staff in April. Analysts don’t expect either of the two recently approved gene therapies to bring in peak sales of more than $100 million annually.”
To read more, click here.
(Source: Endpoints News, September 22nd, 2022)